Reposted by Saad Z. Usmani, MD
Join MSK's @szusmani.bsky.social at #ASCO26 as he presents final results from the DREAMM-9 study evaluating belantamab mafodotin in combination with BVRd for transplant-ineligible patients with newly diagnosed #MultipleMyeloma.
🕒 Friday, May 29 | 3:45 p.m. CDT
Learn more: bit.ly/3PSMIIx